{"gene":"ZNF224","run_date":"2026-04-28T23:00:24","timeline":{"discoveries":[{"year":2005,"finding":"ZNF224 binds in vivo to the distal promoter of the aldolase A gene and represses its transcription; this repression requires the 45-amino acid KRAB A domain and specific interaction with the KAP-1 co-repressor, and also requires histone deacetylases (demonstrated by HDAC1 inhibitor trichostatin A treatment).","method":"Chromatin immunoprecipitation (ChIP), transient transfection/co-transfection reporter assays, HDAC inhibitor treatment, co-repressor interaction studies","journal":"Gene","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (ChIP, reporter assay, mutagenesis of KRAB domain, pharmacological inhibition) in a single study","pmids":["16150558"],"is_preprint":false},{"year":2007,"finding":"ZNF224 is homogeneously distributed in the nucleus and binds the aldolase A negative regulatory element (AldA-NRE) to repress transcription more efficiently than its isoform ZNF255, which localizes to subnuclear structures associated with nucleoli and also to the cytoplasm.","method":"Transient transfection of recombinant proteins, ChIP, northern blot, PCR, immunofluorescence localization","journal":"Gene","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ChIP, reporter assay, localization) with functional consequence","pmids":["17900823"],"is_preprint":false},{"year":2009,"finding":"ZNF224 physically associates with the arginine methyltransferase PRMT5; PRMT5 is recruited to the L-type aldolase A promoter via ZNF224 and catalyzes symmetric dimethylation of arginine 3 of histone H4, contributing to transcriptional repression. PRMT5 knockdown by RNAi relieves repression of the aldolase A promoter.","method":"Co-immunoprecipitation, ChIP, RNA interference, histone methylation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, ChIP, and functional RNAi rescue with multiple orthogonal methods","pmids":["19741270"],"is_preprint":false},{"year":2009,"finding":"ZNF224 was purified from nuclear extracts by DNA affinity chromatography and identified as the transcription factor that binds the 26 bp silencer (-595/-569) of the mitochondrial citrate carrier (CIC) gene; ZNF224 overexpression decreases CIC promoter activity and CIC transcript/protein levels, while ZNF224 silencing activates CIC transcription.","method":"DNA affinity purification, overexpression/silencing reporter assays, RT-PCR, western blot","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — protein purification by DNA affinity combined with gain-of-function and loss-of-function experiments","pmids":["19505435"],"is_preprint":false},{"year":2010,"finding":"DEPDC1 interacts and colocalizes with ZNF224 (a known transcriptional repressor); disruption of the DEPDC1-ZNF224 complex with a cell-permeable peptide induces apoptosis and triggers transcriptional activation of A20, an inhibitor of NF-κB signaling.","method":"Co-immunoprecipitation, immunocytochemistry, cell-permeable peptide inhibition, reporter assay, in vitro and in vivo apoptosis assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — Co-IP plus functional peptide inhibition with mechanistic pathway readout, in vitro and in vivo validation","pmids":["20587513"],"is_preprint":false},{"year":2010,"finding":"ZNF224 interacts with WT1(-KTS) isoform in the nucleus to enhance WT1-mediated transcriptional activation; its isoform ZNF255 interacts with WT1(+KTS) in a different subcellular compartment and participates in RNA processing rather than transcriptional regulation.","method":"Co-immunoprecipitation, subcellular fractionation, co-transfection transcriptional reporter assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP combined with isoform-specific interaction mapping and functional reporter assays","pmids":["20591825"],"is_preprint":false},{"year":2013,"finding":"ZNF224 acts as a co-activator of WT1 on proapoptotic target gene promoters and suppresses WT1-mediated transactivation of antiapoptotic genes in CML K562 cells; cytosine arabinoside (ara-C) induces ZNF224 expression, enhancing apoptotic response.","method":"Co-transfection reporter assays, gene expression analysis, loss-of-function/gain-of-function, drug treatment","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — functional co-factor role established by reporter assay and drug-induced expression, single lab","pmids":["23362234"],"is_preprint":false},{"year":2015,"finding":"BCR-ABL oncogene, via upregulation of WT1, represses transcription of the ZNF224 gene; treatment with imatinib or second-generation tyrosine kinase inhibitors restores ZNF224 expression, placing ZNF224 downstream of BCR-ABL/WT1 in a pathway that controls apoptosis.","method":"Genetic epistasis (BCR-ABL/WT1 manipulation), RT-PCR, western blot, primary CML samples and cell lines, TKI treatment","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — pathway epistasis with primary patient samples and pharmacological validation, single lab","pmids":["26320177"],"is_preprint":false},{"year":2015,"finding":"ZNF224 counteracts WT1-mediated repression of the IRF8 promoter; WT1 recruits ZNF224 to the IRF8 promoter (shown by ChIP), and ZNF224 knockdown suppresses cytarabine-induced IRF8 upregulation in leukemic cells.","method":"ChIP, co-immunoprecipitation, luciferase reporter assay, shRNA knockdown, RT-PCR","journal":"Leukemia research","confidence":"High","confidence_rationale":"Tier 2 — ChIP demonstrating promoter recruitment plus Co-IP, reporter assay, and shRNA validation with multiple orthogonal methods","pmids":["26563595"],"is_preprint":false},{"year":2016,"finding":"ZNF224 binds to the miR-663a promoter via a consensus 5'-CAGC-3' DNA sequence (identified by ChIP-seq and confirmed by ELISA, SPR, and luciferase assay), activating miR-663a transcription; miR-663a then binds the 3' UTR of p53 and p21 to suppress their expression, promoting cell survival.","method":"ChIP-sequencing, ELISA, surface plasmon resonance (SPR), luciferase reporter assay, miRNA inhibitor rescue, qPCR","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1–2 — DNA binding confirmed by multiple biophysical methods (SPR, ELISA, ChIP-seq) plus functional downstream pathway validation","pmids":["27105517"],"is_preprint":false},{"year":2017,"finding":"ZNF224 is a transcriptional repressor of c-Myc in CML; induction of ZNF224 by imatinib or the JAK2 inhibitor AG490 leads to c-Myc transcriptional repression and apoptosis, identifying a ZNF224/c-Myc axis in imatinib responsiveness.","method":"ChIP, reporter assays, qRT-PCR, overexpression/knockdown, pharmacological treatment","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and reporter assay with pharmacological validation, single lab","pmids":["29423056"],"is_preprint":false},{"year":2017,"finding":"MED28 physically interacts with ZNF224 via the KRAB domain of ZNF224 and the MED domain of MED28 in the nucleus; MED28 overexpression stabilizes ZNF224 protein during DNA damage (camptothecin treatment), preventing its degradation and increasing colony formation.","method":"Co-immunoprecipitation, surface plasmon resonance, bimolecular fluorescence complementation (BiFC), western blot, colony formation assay","journal":"Oncology letters","confidence":"High","confidence_rationale":"Tier 1–2 — protein-protein interaction confirmed by SPR (biophysical) and Co-IP, with domain mapping and functional consequence","pmids":["29435049"],"is_preprint":false},{"year":2017,"finding":"ZNF224 positively modulates cyclin D3 gene expression in CLL cells; alteration of ZNF224 expression leads to defects in cell cycle control, and ZNF224 promotes apoptosis resistance in CLL.","method":"Loss-of-function/gain-of-function, gene expression analysis, cell cycle analysis, apoptosis assays","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — clean KD/OE with defined cellular phenotype (cell cycle, apoptosis), single lab","pmids":["28040726"],"is_preprint":false},{"year":2018,"finding":"ZNF224 transcriptionally represses the receptor tyrosine kinase AXL in CML cells; ZNF224 overexpression in imatinib-resistant CML cells suppresses AXL expression and partially restores imatinib sensitivity.","method":"Overexpression, qRT-PCR, western blot, luciferase reporter assay, cell viability assay","journal":"Biochimie","confidence":"Medium","confidence_rationale":"Tier 2 — defined target gene repression with reporter validation and functional drug-response readout, single lab","pmids":["30176265"],"is_preprint":false},{"year":2021,"finding":"ZNF224 expression is induced by TGF-β in melanoma cells; ZNF224 potentiates TGF-β-induced activation of EMT target genes and positively modulates TGF-β, TβR1, and TβR2 expression, creating a positive regulatory loop that enhances EMT and invasiveness.","method":"Overexpression, knockdown (siRNA), gene expression analysis, invasion/proliferation assays, TGF-β stimulation experiments","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function with defined EMT phenotypic readout and pathway placement, single lab","pmids":["34181020"],"is_preprint":false},{"year":2022,"finding":"ZNF224 knockdown reduces NF-κB pathway activity in CLL cells, raises spontaneous and drug-induced apoptosis, and inhibits proliferation of primary CLL cells, placing ZNF224 as a positive regulator of NF-κB survival signaling in CLL.","method":"RNA interference, NF-κB activity assays, apoptosis assays, primary patient cells","journal":"Frontiers in molecular biosciences","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined pathway readout in primary patient cells, single lab","pmids":["36425656"],"is_preprint":false},{"year":2025,"finding":"ZNF224 overexpression in melanoma cells promotes p21(CIP1/WAF1) gene transcription in a p53-dependent manner, and also enhances AKT-triggered cytosolic retention of p21 protein, thereby inhibiting apoptosis and favoring cell proliferation.","method":"Overexpression, gene expression analysis, reporter assays, AKT pathway inhibition, subcellular fractionation, transcriptomic data analysis","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic dissection with p53-dependent transcriptional and AKT-dependent post-translational pathway components, single lab","pmids":["40321146"],"is_preprint":false}],"current_model":"ZNF224 is a KRAB-domain-containing Krüppel-like zinc finger transcription factor that represses target gene transcription (aldolase A, CIC, c-Myc, AXL) by recruiting the co-repressor KAP-1 and the arginine methyltransferase PRMT5 (which symmetrically dimethylates H4R3) to target promoters, and also acts as a context-dependent transcriptional co-factor for WT1, enhancing or dampening WT1 activity depending on the promoter and partner isoform; its activity is regulated by protein partners (DEPDC1, MED28, WT1), post-translational stability control during DNA damage, and upstream oncogenic signaling (BCR-ABL/JAK2/TGF-β), with functional consequences for apoptosis, cell cycle, EMT, and NF-κB pathway control in multiple cancer types."},"narrative":{"teleology":[{"year":2005,"claim":"The molecular mechanism by which ZNF224 represses transcription was established: ZNF224 binds the aldolase A promoter in vivo and requires its KRAB-A domain for KAP-1 co-repressor recruitment and HDAC-dependent silencing, defining it as a KRAB-ZFP transcriptional repressor.","evidence":"ChIP, KRAB domain mutagenesis, reporter assays, and TSA treatment in human cells","pmids":["16150558"],"confidence":"High","gaps":["No genome-wide target repertoire defined","Specific HDAC isoform(s) involved not identified"]},{"year":2007,"claim":"Comparative analysis with isoform ZNF255 showed ZNF224 is homogeneously nuclear and a more potent repressor, distinguishing the functional specialization of these paralogous isoforms.","evidence":"Immunofluorescence, ChIP, and reporter assays comparing ZNF224 and ZNF255","pmids":["17900823"],"confidence":"High","gaps":["Determinants of differential subnuclear distribution not mapped"]},{"year":2009,"claim":"A chromatin-level repressive mechanism was resolved: ZNF224 recruits the arginine methyltransferase PRMT5 to target promoters, where PRMT5 symmetrically dimethylates H4R3, and PRMT5 knockdown relieves repression — establishing a histone-modification arm of ZNF224-mediated silencing beyond HDACs.","evidence":"Reciprocal Co-IP, ChIP for histone marks, RNAi of PRMT5, histone methylation assays","pmids":["19741270"],"confidence":"High","gaps":["Whether PRMT5 and HDAC act sequentially or in parallel not determined","Generality of PRMT5 recruitment to other ZNF224 targets unknown"]},{"year":2009,"claim":"A second direct transcriptional target was identified: ZNF224 was biochemically purified as the factor binding the CIC gene silencer, extending its repressor role to metabolite transport genes.","evidence":"DNA affinity purification from nuclear extracts, overexpression/silencing reporter assays, RT-PCR","pmids":["19505435"],"confidence":"High","gaps":["Whether CIC repression also involves PRMT5/KAP-1 not tested"]},{"year":2010,"claim":"Two new functional partnerships were discovered: DEPDC1 interacts with ZNF224 to co-repress the NF-κB inhibitor A20 (disruption induces apoptosis), and WT1(-KTS) interacts with ZNF224 to enhance transcriptional activation — revealing ZNF224 can switch from repressor to co-activator depending on its protein partner.","evidence":"Co-IP, cell-permeable peptide disruption, reporter assays, apoptosis assays (DEPDC1); Co-IP, subcellular fractionation, reporter assays (WT1)","pmids":["20587513","20591825"],"confidence":"High","gaps":["Structural basis of DEPDC1–ZNF224 versus WT1–ZNF224 complex specificity unknown","Genomic targets co-regulated by DEPDC1–ZNF224 not mapped"]},{"year":2013,"claim":"The context-dependent co-factor role of ZNF224 with WT1 was elaborated: on proapoptotic promoters ZNF224 enhances WT1 activation, while on antiapoptotic promoters it suppresses WT1 activity, and cytarabine induces ZNF224 to potentiate apoptosis in CML cells.","evidence":"Co-transfection reporter assays, gene expression profiling, drug treatment in K562 CML cells","pmids":["23362234"],"confidence":"Medium","gaps":["Promoter features that determine co-activation versus co-repression not defined","Single lab/cell line system"]},{"year":2015,"claim":"ZNF224 was placed within the BCR-ABL signaling axis: BCR-ABL via WT1 represses ZNF224, and TKI treatment restores its expression; independently, ZNF224 counteracts WT1 repression at the IRF8 promoter, linking ZNF224 to innate immune gene regulation in leukemia.","evidence":"Epistasis experiments with BCR-ABL/WT1, TKI treatment, primary CML samples; ChIP at IRF8 promoter, shRNA knockdown","pmids":["26320177","26563595"],"confidence":"High","gaps":["Whether ZNF224 restoration is required for full TKI cytotoxicity not shown in vivo"]},{"year":2016,"claim":"A genome-wide DNA binding motif (5′-CAGC-3′) was identified for ZNF224 by ChIP-seq, and a direct transcriptional activation target, miR-663a, was characterized; miR-663a in turn suppresses p53 and p21, revealing a ZNF224–miRNA–p53 signaling cascade.","evidence":"ChIP-seq, SPR, ELISA, luciferase reporter, miRNA inhibitor rescue","pmids":["27105517"],"confidence":"High","gaps":["Full ChIP-seq target catalog not published","How ZNF224 switches from repression to activation at this locus not explained"]},{"year":2017,"claim":"ZNF224 was shown to directly repress c-Myc transcription in CML cells upon TKI/JAK2 inhibitor treatment, extending its repressor targets to a master oncogene; separately, MED28 was identified as a physical partner that stabilizes ZNF224 protein during DNA damage via KRAB domain interaction.","evidence":"ChIP and reporter assays for c-Myc; Co-IP, SPR, BiFC for MED28 interaction; colony formation after camptothecin","pmids":["29423056","29435049"],"confidence":"High","gaps":["Ubiquitin-proteasome pathway regulating ZNF224 turnover not identified","Whether MED28 stabilization affects all ZNF224 targets not tested"]},{"year":2017,"claim":"In CLL, ZNF224 was found to positively regulate cyclin D3 expression and influence cell cycle progression and apoptosis resistance, broadening its oncogenic role beyond CML.","evidence":"Knockdown and overexpression with cell cycle and apoptosis readouts in CLL cells","pmids":["28040726"],"confidence":"Medium","gaps":["Direct versus indirect regulation of CCND3 promoter not resolved","Patient cohort functional validation lacking"]},{"year":2018,"claim":"ZNF224 was shown to transcriptionally repress AXL in CML, and its overexpression partially restores imatinib sensitivity in resistant cells, connecting ZNF224 loss to drug resistance mechanisms.","evidence":"Overexpression, reporter assay, viability assay in imatinib-resistant CML cells","pmids":["30176265"],"confidence":"Medium","gaps":["In vivo drug resistance model not tested","ChIP confirmation of direct AXL promoter binding not provided"]},{"year":2021,"claim":"Beyond hematopoietic malignancies, ZNF224 was shown to be TGF-β-inducible in melanoma and to potentiate EMT through a positive feedback loop upregulating TGF-β pathway components, establishing a role in epithelial plasticity.","evidence":"siRNA/overexpression, invasion assays, gene expression analysis, TGF-β stimulation in melanoma cells","pmids":["34181020"],"confidence":"Medium","gaps":["Direct DNA-binding targets mediating EMT not identified","In vivo metastasis data absent"]},{"year":2022,"claim":"ZNF224 was functionally linked to NF-κB pathway activation in CLL: its knockdown reduces NF-κB activity and increases apoptosis in primary patient cells, establishing a pro-survival role through NF-κB.","evidence":"RNAi, NF-κB activity assays, apoptosis assays in primary CLL cells","pmids":["36425656"],"confidence":"Medium","gaps":["Whether NF-κB regulation is direct or via A20/DEPDC1 axis not clarified in CLL context"]},{"year":2025,"claim":"In melanoma, ZNF224 was found to promote p21 transcription in a p53-dependent manner yet simultaneously enhance AKT-mediated cytosolic retention of p21 protein, converting p21 from a tumor suppressor to a proliferation-promoting factor — reconciling the paradox of ZNF224 activating p21 while promoting survival.","evidence":"Overexpression, reporter assays, AKT inhibition, subcellular fractionation, transcriptomic analysis in melanoma cells","pmids":["40321146"],"confidence":"Medium","gaps":["AKT activation mechanism by ZNF224 not identified","Single cell line system"]},{"year":null,"claim":"Key unresolved questions include the structural basis for ZNF224's context-dependent switch between repression and activation, the complete genome-wide target repertoire, the E3 ligase(s) controlling its proteasomal turnover, and whether its dual roles in leukemia and solid tumors reflect shared or distinct molecular mechanisms.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure available","Genome-wide direct target catalog from ChIP-seq not published in full","Ubiquitin ligase for ZNF224 degradation not identified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,3,9]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,6,9,10,14,16]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,5,11]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,3,9,10]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[2]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4,6]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[14,15,16]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[12]}],"complexes":[],"partners":["KAP1","PRMT5","DEPDC1","WT1","MED28"],"other_free_text":[]},"mechanistic_narrative":"ZNF224 is a KRAB-domain zinc finger transcription factor that functions as both a transcriptional repressor and a context-dependent transcriptional co-activator, integrating chromatin-modifying activities with oncogenic and stress signaling pathways. As a repressor, ZNF224 binds specific promoter elements (aldolase A, CIC, c-Myc, AXL) and recruits the KAP-1 co-repressor and the arginine methyltransferase PRMT5, which catalyzes symmetric dimethylation of histone H4R3, with repression also requiring HDAC activity [PMID:16150558, PMID:19741270, PMID:19505435, PMID:29423056]. As a co-factor for WT1, ZNF224 enhances WT1-mediated activation of proapoptotic genes and counteracts WT1 repression at other promoters such as IRF8, with its own expression regulated downstream of BCR-ABL/WT1 signaling and restored by tyrosine kinase inhibitors [PMID:20591825, PMID:23362234, PMID:26563595, PMID:26320177]. ZNF224 also activates miR-663a transcription to suppress p53/p21, promotes TGF-β-driven EMT in melanoma, sustains NF-κB survival signaling and cyclin D3 expression in CLL, and is stabilized during DNA damage by MED28 interaction via the KRAB domain [PMID:27105517, PMID:34181020, PMID:36425656, PMID:28040726, PMID:29435049]."},"prefetch_data":{"uniprot":{"accession":"Q9NZL3","full_name":"Zinc finger protein 224","aliases":["Bone marrow zinc finger 2","BMZF-2","Zinc finger protein 233","Zinc finger protein 255","Zinc finger protein 27","Zinc finger protein KOX22"],"length_aa":707,"mass_kda":82.3,"function":"May be involved in transcriptional regulation as a transcriptional repressor. The DEPDC1A-ZNF224 complex may play a critical role in bladder carcinogenesis by repressing the transcription of the A20 gene, leading to transport of NF-KB protein into the nucleus, resulting in suppression of apoptosis of bladder cancer cells","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9NZL3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZNF224","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ZNF224","total_profiled":1310},"omim":[{"mim_id":"616888","title":"TRANSMEMBRANE PROTEIN 8B; TMEM8B","url":"https://www.omim.org/entry/616888"},{"mim_id":"607102","title":"WT1 TRANSCRIPTION FACTOR; WT1","url":"https://www.omim.org/entry/607102"},{"mim_id":"606956","title":"ZINC FINGER PROTEIN 256; ZNF256","url":"https://www.omim.org/entry/606956"},{"mim_id":"194555","title":"ZINC FINGER PROTEIN 224; ZNF224","url":"https://www.omim.org/entry/194555"},{"mim_id":"194554","title":"ZINC FINGER PROTEIN 45; ZNF45","url":"https://www.omim.org/entry/194554"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZNF224"},"hgnc":{"alias_symbol":["BMZF-2","KOX22"],"prev_symbol":["ZNF255","ZNF27"]},"alphafold":{"accession":"Q9NZL3","domains":[{"cath_id":"3.30.160.60","chopping":"261-312","consensus_level":"medium","plddt":84.3981,"start":261,"end":312},{"cath_id":"3.30.160.60","chopping":"317-428","consensus_level":"medium","plddt":88.2854,"start":317,"end":428},{"cath_id":"3.30.160.60","chopping":"457-535","consensus_level":"medium","plddt":86.9359,"start":457,"end":535},{"cath_id":"3.30.160.60","chopping":"539-620","consensus_level":"medium","plddt":83.28,"start":539,"end":620},{"cath_id":"1.10.1200","chopping":"11-43","consensus_level":"medium","plddt":66.587,"start":11,"end":43}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NZL3","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NZL3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NZL3-F1-predicted_aligned_error_v6.png","plddt_mean":70.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZNF224","jax_strain_url":"https://www.jax.org/strain/search?query=ZNF224"},"sequence":{"accession":"Q9NZL3","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NZL3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NZL3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NZL3"}},"corpus_meta":[{"pmid":"20587513","id":"PMC_20587513","title":"Cell-permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression and oncogenicity in bladder cancer cells.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20587513","citation_count":86,"is_preprint":false},{"pmid":"16150558","id":"PMC_16150558","title":"The Krüppel-like zinc-finger protein ZNF224 represses aldolase A gene transcription by interacting with the KAP-1 co-repressor protein.","date":"2005","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/16150558","citation_count":33,"is_preprint":false},{"pmid":"19741270","id":"PMC_19741270","title":"The Kruppel-like zinc finger protein ZNF224 recruits the arginine methyltransferase PRMT5 on the transcriptional repressor complex of the aldolase A gene.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19741270","citation_count":31,"is_preprint":false},{"pmid":"27105517","id":"PMC_27105517","title":"ZNF224, Krüppel like zinc finger protein, induces cell growth and apoptosis-resistance by down-regulation of p21 and p53 via miR-663a.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27105517","citation_count":31,"is_preprint":false},{"pmid":"20591825","id":"PMC_20591825","title":"Biochemical and functional interaction between ZNF224 and ZNF255, two members of the Kruppel-like zinc-finger protein family and WT1 protein isoforms.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20591825","citation_count":26,"is_preprint":false},{"pmid":"19505435","id":"PMC_19505435","title":"Transcription of the mitochondrial citrate carrier gene: identification of a silencer and its binding protein ZNF224.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19505435","citation_count":24,"is_preprint":false},{"pmid":"23362234","id":"PMC_23362234","title":"Role of WT1-ZNF224 interaction in the expression of apoptosis-regulating genes.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23362234","citation_count":22,"is_preprint":false},{"pmid":"26320177","id":"PMC_26320177","title":"WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26320177","citation_count":19,"is_preprint":false},{"pmid":"34181020","id":"PMC_34181020","title":"ZNF224 is a mediator of TGF-β pro-oncogenic function in melanoma.","date":"2021","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34181020","citation_count":16,"is_preprint":false},{"pmid":"29423056","id":"PMC_29423056","title":"Role of ZNF224 in c-Myc repression and imatinib responsiveness in chronic myeloid leukemia.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29423056","citation_count":15,"is_preprint":false},{"pmid":"26563595","id":"PMC_26563595","title":"The hematopoietic tumor suppressor interferon regulatory factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms' tumor gene 1 (WT1) protein.","date":"2015","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/26563595","citation_count":15,"is_preprint":false},{"pmid":"21187159","id":"PMC_21187159","title":"ZNF224: Structure and role of a multifunctional KRAB-ZFP protein.","date":"2010","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21187159","citation_count":14,"is_preprint":false},{"pmid":"28040726","id":"PMC_28040726","title":"Role of ZNF224 in cell growth and chemoresistance of chronic lymphocitic leukemia.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28040726","citation_count":14,"is_preprint":false},{"pmid":"17900823","id":"PMC_17900823","title":"Differential expression and cellular localization of ZNF224 and ZNF255, two isoforms of the Krüppel-like zinc-finger protein family.","date":"2007","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/17900823","citation_count":14,"is_preprint":false},{"pmid":"28215224","id":"PMC_28215224","title":"The Complex Role of the ZNF224 Transcription Factor in Cancer.","date":"2016","source":"Advances in protein chemistry and structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/28215224","citation_count":12,"is_preprint":false},{"pmid":"30176265","id":"PMC_30176265","title":"ZNF224 is a transcriptional repressor of AXL in chronic myeloid leukemia cells.","date":"2018","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/30176265","citation_count":12,"is_preprint":false},{"pmid":"29435049","id":"PMC_29435049","title":"MED28 increases the colony-forming ability of breast cancer cells by stabilizing the ZNF224 protein upon DNA damage.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/29435049","citation_count":9,"is_preprint":false},{"pmid":"36425656","id":"PMC_36425656","title":"Biological relevance of ZNF224 expression in chronic lymphocytic leukemia and its implication IN NF-kB pathway regulation.","date":"2022","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/36425656","citation_count":7,"is_preprint":false},{"pmid":"34684876","id":"PMC_34684876","title":"ZNF224 Protein: Multifaceted Functions Based on Its Molecular Partners.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34684876","citation_count":6,"is_preprint":false},{"pmid":"40321146","id":"PMC_40321146","title":"ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma.","date":"2025","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/40321146","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9909,"output_tokens":3864,"usd":0.043844},"stage2":{"model":"claude-opus-4-6","input_tokens":7350,"output_tokens":3486,"usd":0.18585},"total_usd":0.229694,"stage1_batch_id":"msgbatch_01BparvgRZ9S2LMidvaoo86K","stage2_batch_id":"msgbatch_01NkBfv9SVZWthhS7j6mU6G3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"ZNF224 binds in vivo to the distal promoter of the aldolase A gene and represses its transcription; this repression requires the 45-amino acid KRAB A domain and specific interaction with the KAP-1 co-repressor, and also requires histone deacetylases (demonstrated by HDAC1 inhibitor trichostatin A treatment).\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), transient transfection/co-transfection reporter assays, HDAC inhibitor treatment, co-repressor interaction studies\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (ChIP, reporter assay, mutagenesis of KRAB domain, pharmacological inhibition) in a single study\",\n      \"pmids\": [\"16150558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ZNF224 is homogeneously distributed in the nucleus and binds the aldolase A negative regulatory element (AldA-NRE) to repress transcription more efficiently than its isoform ZNF255, which localizes to subnuclear structures associated with nucleoli and also to the cytoplasm.\",\n      \"method\": \"Transient transfection of recombinant proteins, ChIP, northern blot, PCR, immunofluorescence localization\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP, reporter assay, localization) with functional consequence\",\n      \"pmids\": [\"17900823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ZNF224 physically associates with the arginine methyltransferase PRMT5; PRMT5 is recruited to the L-type aldolase A promoter via ZNF224 and catalyzes symmetric dimethylation of arginine 3 of histone H4, contributing to transcriptional repression. PRMT5 knockdown by RNAi relieves repression of the aldolase A promoter.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, RNA interference, histone methylation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, ChIP, and functional RNAi rescue with multiple orthogonal methods\",\n      \"pmids\": [\"19741270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ZNF224 was purified from nuclear extracts by DNA affinity chromatography and identified as the transcription factor that binds the 26 bp silencer (-595/-569) of the mitochondrial citrate carrier (CIC) gene; ZNF224 overexpression decreases CIC promoter activity and CIC transcript/protein levels, while ZNF224 silencing activates CIC transcription.\",\n      \"method\": \"DNA affinity purification, overexpression/silencing reporter assays, RT-PCR, western blot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — protein purification by DNA affinity combined with gain-of-function and loss-of-function experiments\",\n      \"pmids\": [\"19505435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"DEPDC1 interacts and colocalizes with ZNF224 (a known transcriptional repressor); disruption of the DEPDC1-ZNF224 complex with a cell-permeable peptide induces apoptosis and triggers transcriptional activation of A20, an inhibitor of NF-κB signaling.\",\n      \"method\": \"Co-immunoprecipitation, immunocytochemistry, cell-permeable peptide inhibition, reporter assay, in vitro and in vivo apoptosis assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus functional peptide inhibition with mechanistic pathway readout, in vitro and in vivo validation\",\n      \"pmids\": [\"20587513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZNF224 interacts with WT1(-KTS) isoform in the nucleus to enhance WT1-mediated transcriptional activation; its isoform ZNF255 interacts with WT1(+KTS) in a different subcellular compartment and participates in RNA processing rather than transcriptional regulation.\",\n      \"method\": \"Co-immunoprecipitation, subcellular fractionation, co-transfection transcriptional reporter assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP combined with isoform-specific interaction mapping and functional reporter assays\",\n      \"pmids\": [\"20591825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ZNF224 acts as a co-activator of WT1 on proapoptotic target gene promoters and suppresses WT1-mediated transactivation of antiapoptotic genes in CML K562 cells; cytosine arabinoside (ara-C) induces ZNF224 expression, enhancing apoptotic response.\",\n      \"method\": \"Co-transfection reporter assays, gene expression analysis, loss-of-function/gain-of-function, drug treatment\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional co-factor role established by reporter assay and drug-induced expression, single lab\",\n      \"pmids\": [\"23362234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BCR-ABL oncogene, via upregulation of WT1, represses transcription of the ZNF224 gene; treatment with imatinib or second-generation tyrosine kinase inhibitors restores ZNF224 expression, placing ZNF224 downstream of BCR-ABL/WT1 in a pathway that controls apoptosis.\",\n      \"method\": \"Genetic epistasis (BCR-ABL/WT1 manipulation), RT-PCR, western blot, primary CML samples and cell lines, TKI treatment\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway epistasis with primary patient samples and pharmacological validation, single lab\",\n      \"pmids\": [\"26320177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ZNF224 counteracts WT1-mediated repression of the IRF8 promoter; WT1 recruits ZNF224 to the IRF8 promoter (shown by ChIP), and ZNF224 knockdown suppresses cytarabine-induced IRF8 upregulation in leukemic cells.\",\n      \"method\": \"ChIP, co-immunoprecipitation, luciferase reporter assay, shRNA knockdown, RT-PCR\",\n      \"journal\": \"Leukemia research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP demonstrating promoter recruitment plus Co-IP, reporter assay, and shRNA validation with multiple orthogonal methods\",\n      \"pmids\": [\"26563595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZNF224 binds to the miR-663a promoter via a consensus 5'-CAGC-3' DNA sequence (identified by ChIP-seq and confirmed by ELISA, SPR, and luciferase assay), activating miR-663a transcription; miR-663a then binds the 3' UTR of p53 and p21 to suppress their expression, promoting cell survival.\",\n      \"method\": \"ChIP-sequencing, ELISA, surface plasmon resonance (SPR), luciferase reporter assay, miRNA inhibitor rescue, qPCR\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — DNA binding confirmed by multiple biophysical methods (SPR, ELISA, ChIP-seq) plus functional downstream pathway validation\",\n      \"pmids\": [\"27105517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZNF224 is a transcriptional repressor of c-Myc in CML; induction of ZNF224 by imatinib or the JAK2 inhibitor AG490 leads to c-Myc transcriptional repression and apoptosis, identifying a ZNF224/c-Myc axis in imatinib responsiveness.\",\n      \"method\": \"ChIP, reporter assays, qRT-PCR, overexpression/knockdown, pharmacological treatment\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and reporter assay with pharmacological validation, single lab\",\n      \"pmids\": [\"29423056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MED28 physically interacts with ZNF224 via the KRAB domain of ZNF224 and the MED domain of MED28 in the nucleus; MED28 overexpression stabilizes ZNF224 protein during DNA damage (camptothecin treatment), preventing its degradation and increasing colony formation.\",\n      \"method\": \"Co-immunoprecipitation, surface plasmon resonance, bimolecular fluorescence complementation (BiFC), western blot, colony formation assay\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — protein-protein interaction confirmed by SPR (biophysical) and Co-IP, with domain mapping and functional consequence\",\n      \"pmids\": [\"29435049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZNF224 positively modulates cyclin D3 gene expression in CLL cells; alteration of ZNF224 expression leads to defects in cell cycle control, and ZNF224 promotes apoptosis resistance in CLL.\",\n      \"method\": \"Loss-of-function/gain-of-function, gene expression analysis, cell cycle analysis, apoptosis assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD/OE with defined cellular phenotype (cell cycle, apoptosis), single lab\",\n      \"pmids\": [\"28040726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ZNF224 transcriptionally represses the receptor tyrosine kinase AXL in CML cells; ZNF224 overexpression in imatinib-resistant CML cells suppresses AXL expression and partially restores imatinib sensitivity.\",\n      \"method\": \"Overexpression, qRT-PCR, western blot, luciferase reporter assay, cell viability assay\",\n      \"journal\": \"Biochimie\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined target gene repression with reporter validation and functional drug-response readout, single lab\",\n      \"pmids\": [\"30176265\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZNF224 expression is induced by TGF-β in melanoma cells; ZNF224 potentiates TGF-β-induced activation of EMT target genes and positively modulates TGF-β, TβR1, and TβR2 expression, creating a positive regulatory loop that enhances EMT and invasiveness.\",\n      \"method\": \"Overexpression, knockdown (siRNA), gene expression analysis, invasion/proliferation assays, TGF-β stimulation experiments\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with defined EMT phenotypic readout and pathway placement, single lab\",\n      \"pmids\": [\"34181020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF224 knockdown reduces NF-κB pathway activity in CLL cells, raises spontaneous and drug-induced apoptosis, and inhibits proliferation of primary CLL cells, placing ZNF224 as a positive regulator of NF-κB survival signaling in CLL.\",\n      \"method\": \"RNA interference, NF-κB activity assays, apoptosis assays, primary patient cells\",\n      \"journal\": \"Frontiers in molecular biosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined pathway readout in primary patient cells, single lab\",\n      \"pmids\": [\"36425656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF224 overexpression in melanoma cells promotes p21(CIP1/WAF1) gene transcription in a p53-dependent manner, and also enhances AKT-triggered cytosolic retention of p21 protein, thereby inhibiting apoptosis and favoring cell proliferation.\",\n      \"method\": \"Overexpression, gene expression analysis, reporter assays, AKT pathway inhibition, subcellular fractionation, transcriptomic data analysis\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with p53-dependent transcriptional and AKT-dependent post-translational pathway components, single lab\",\n      \"pmids\": [\"40321146\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZNF224 is a KRAB-domain-containing Krüppel-like zinc finger transcription factor that represses target gene transcription (aldolase A, CIC, c-Myc, AXL) by recruiting the co-repressor KAP-1 and the arginine methyltransferase PRMT5 (which symmetrically dimethylates H4R3) to target promoters, and also acts as a context-dependent transcriptional co-factor for WT1, enhancing or dampening WT1 activity depending on the promoter and partner isoform; its activity is regulated by protein partners (DEPDC1, MED28, WT1), post-translational stability control during DNA damage, and upstream oncogenic signaling (BCR-ABL/JAK2/TGF-β), with functional consequences for apoptosis, cell cycle, EMT, and NF-κB pathway control in multiple cancer types.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ZNF224 is a KRAB-domain zinc finger transcription factor that functions as both a transcriptional repressor and a context-dependent transcriptional co-activator, integrating chromatin-modifying activities with oncogenic and stress signaling pathways. As a repressor, ZNF224 binds specific promoter elements (aldolase A, CIC, c-Myc, AXL) and recruits the KAP-1 co-repressor and the arginine methyltransferase PRMT5, which catalyzes symmetric dimethylation of histone H4R3, with repression also requiring HDAC activity [PMID:16150558, PMID:19741270, PMID:19505435, PMID:29423056]. As a co-factor for WT1, ZNF224 enhances WT1-mediated activation of proapoptotic genes and counteracts WT1 repression at other promoters such as IRF8, with its own expression regulated downstream of BCR-ABL/WT1 signaling and restored by tyrosine kinase inhibitors [PMID:20591825, PMID:23362234, PMID:26563595, PMID:26320177]. ZNF224 also activates miR-663a transcription to suppress p53/p21, promotes TGF-β-driven EMT in melanoma, sustains NF-κB survival signaling and cyclin D3 expression in CLL, and is stabilized during DNA damage by MED28 interaction via the KRAB domain [PMID:27105517, PMID:34181020, PMID:36425656, PMID:28040726, PMID:29435049].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"The molecular mechanism by which ZNF224 represses transcription was established: ZNF224 binds the aldolase A promoter in vivo and requires its KRAB-A domain for KAP-1 co-repressor recruitment and HDAC-dependent silencing, defining it as a KRAB-ZFP transcriptional repressor.\",\n      \"evidence\": \"ChIP, KRAB domain mutagenesis, reporter assays, and TSA treatment in human cells\",\n      \"pmids\": [\"16150558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No genome-wide target repertoire defined\", \"Specific HDAC isoform(s) involved not identified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Comparative analysis with isoform ZNF255 showed ZNF224 is homogeneously nuclear and a more potent repressor, distinguishing the functional specialization of these paralogous isoforms.\",\n      \"evidence\": \"Immunofluorescence, ChIP, and reporter assays comparing ZNF224 and ZNF255\",\n      \"pmids\": [\"17900823\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of differential subnuclear distribution not mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"A chromatin-level repressive mechanism was resolved: ZNF224 recruits the arginine methyltransferase PRMT5 to target promoters, where PRMT5 symmetrically dimethylates H4R3, and PRMT5 knockdown relieves repression — establishing a histone-modification arm of ZNF224-mediated silencing beyond HDACs.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP for histone marks, RNAi of PRMT5, histone methylation assays\",\n      \"pmids\": [\"19741270\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PRMT5 and HDAC act sequentially or in parallel not determined\", \"Generality of PRMT5 recruitment to other ZNF224 targets unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"A second direct transcriptional target was identified: ZNF224 was biochemically purified as the factor binding the CIC gene silencer, extending its repressor role to metabolite transport genes.\",\n      \"evidence\": \"DNA affinity purification from nuclear extracts, overexpression/silencing reporter assays, RT-PCR\",\n      \"pmids\": [\"19505435\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CIC repression also involves PRMT5/KAP-1 not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Two new functional partnerships were discovered: DEPDC1 interacts with ZNF224 to co-repress the NF-κB inhibitor A20 (disruption induces apoptosis), and WT1(-KTS) interacts with ZNF224 to enhance transcriptional activation — revealing ZNF224 can switch from repressor to co-activator depending on its protein partner.\",\n      \"evidence\": \"Co-IP, cell-permeable peptide disruption, reporter assays, apoptosis assays (DEPDC1); Co-IP, subcellular fractionation, reporter assays (WT1)\",\n      \"pmids\": [\"20587513\", \"20591825\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of DEPDC1–ZNF224 versus WT1–ZNF224 complex specificity unknown\", \"Genomic targets co-regulated by DEPDC1–ZNF224 not mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"The context-dependent co-factor role of ZNF224 with WT1 was elaborated: on proapoptotic promoters ZNF224 enhances WT1 activation, while on antiapoptotic promoters it suppresses WT1 activity, and cytarabine induces ZNF224 to potentiate apoptosis in CML cells.\",\n      \"evidence\": \"Co-transfection reporter assays, gene expression profiling, drug treatment in K562 CML cells\",\n      \"pmids\": [\"23362234\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Promoter features that determine co-activation versus co-repression not defined\", \"Single lab/cell line system\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"ZNF224 was placed within the BCR-ABL signaling axis: BCR-ABL via WT1 represses ZNF224, and TKI treatment restores its expression; independently, ZNF224 counteracts WT1 repression at the IRF8 promoter, linking ZNF224 to innate immune gene regulation in leukemia.\",\n      \"evidence\": \"Epistasis experiments with BCR-ABL/WT1, TKI treatment, primary CML samples; ChIP at IRF8 promoter, shRNA knockdown\",\n      \"pmids\": [\"26320177\", \"26563595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ZNF224 restoration is required for full TKI cytotoxicity not shown in vivo\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A genome-wide DNA binding motif (5′-CAGC-3′) was identified for ZNF224 by ChIP-seq, and a direct transcriptional activation target, miR-663a, was characterized; miR-663a in turn suppresses p53 and p21, revealing a ZNF224–miRNA–p53 signaling cascade.\",\n      \"evidence\": \"ChIP-seq, SPR, ELISA, luciferase reporter, miRNA inhibitor rescue\",\n      \"pmids\": [\"27105517\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full ChIP-seq target catalog not published\", \"How ZNF224 switches from repression to activation at this locus not explained\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"ZNF224 was shown to directly repress c-Myc transcription in CML cells upon TKI/JAK2 inhibitor treatment, extending its repressor targets to a master oncogene; separately, MED28 was identified as a physical partner that stabilizes ZNF224 protein during DNA damage via KRAB domain interaction.\",\n      \"evidence\": \"ChIP and reporter assays for c-Myc; Co-IP, SPR, BiFC for MED28 interaction; colony formation after camptothecin\",\n      \"pmids\": [\"29423056\", \"29435049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ubiquitin-proteasome pathway regulating ZNF224 turnover not identified\", \"Whether MED28 stabilization affects all ZNF224 targets not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"In CLL, ZNF224 was found to positively regulate cyclin D3 expression and influence cell cycle progression and apoptosis resistance, broadening its oncogenic role beyond CML.\",\n      \"evidence\": \"Knockdown and overexpression with cell cycle and apoptosis readouts in CLL cells\",\n      \"pmids\": [\"28040726\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect regulation of CCND3 promoter not resolved\", \"Patient cohort functional validation lacking\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"ZNF224 was shown to transcriptionally repress AXL in CML, and its overexpression partially restores imatinib sensitivity in resistant cells, connecting ZNF224 loss to drug resistance mechanisms.\",\n      \"evidence\": \"Overexpression, reporter assay, viability assay in imatinib-resistant CML cells\",\n      \"pmids\": [\"30176265\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo drug resistance model not tested\", \"ChIP confirmation of direct AXL promoter binding not provided\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Beyond hematopoietic malignancies, ZNF224 was shown to be TGF-β-inducible in melanoma and to potentiate EMT through a positive feedback loop upregulating TGF-β pathway components, establishing a role in epithelial plasticity.\",\n      \"evidence\": \"siRNA/overexpression, invasion assays, gene expression analysis, TGF-β stimulation in melanoma cells\",\n      \"pmids\": [\"34181020\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct DNA-binding targets mediating EMT not identified\", \"In vivo metastasis data absent\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"ZNF224 was functionally linked to NF-κB pathway activation in CLL: its knockdown reduces NF-κB activity and increases apoptosis in primary patient cells, establishing a pro-survival role through NF-κB.\",\n      \"evidence\": \"RNAi, NF-κB activity assays, apoptosis assays in primary CLL cells\",\n      \"pmids\": [\"36425656\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether NF-κB regulation is direct or via A20/DEPDC1 axis not clarified in CLL context\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"In melanoma, ZNF224 was found to promote p21 transcription in a p53-dependent manner yet simultaneously enhance AKT-mediated cytosolic retention of p21 protein, converting p21 from a tumor suppressor to a proliferation-promoting factor — reconciling the paradox of ZNF224 activating p21 while promoting survival.\",\n      \"evidence\": \"Overexpression, reporter assays, AKT inhibition, subcellular fractionation, transcriptomic analysis in melanoma cells\",\n      \"pmids\": [\"40321146\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"AKT activation mechanism by ZNF224 not identified\", \"Single cell line system\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for ZNF224's context-dependent switch between repression and activation, the complete genome-wide target repertoire, the E3 ligase(s) controlling its proteasomal turnover, and whether its dual roles in leukemia and solid tumors reflect shared or distinct molecular mechanisms.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure available\", \"Genome-wide direct target catalog from ChIP-seq not published in full\", \"Ubiquitin ligase for ZNF224 degradation not identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 3, 9]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 6, 9, 10, 14, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 5, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 3, 9, 10]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [14, 15, 16]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"KAP1\",\n      \"PRMT5\",\n      \"DEPDC1\",\n      \"WT1\",\n      \"MED28\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}